LONDON and NEW YORK, December 11, 2013 /PRNewswire/ --
According to ABMRG, a global authority on medtech market intelligence, the global coronary stent market is expected to be over $13 billion by 2019, despite the current downward trend in the US, the largest market, and declining selling prices globally. "Increasing PCI procedures triggered by the rising prevalence of CAD, novel technologies in pipeline addressing the unmet needs, uptake of Bioabsorbable stents and impressive growth in APAC region have the potential to upswing the fortunes of the market that has been remaining stagnant for a few years," said ABMRG CEO Manoj Jiandani.
The market study takes into account various global clinical studies and pipeline products and it suggests that the coronary stent pipeline is clustered with new generation Drug Eluting Stent (DES), bioabsorbable technology and stents for the niche segments such as complex and bifurcated vessels. "Altering the trend, small to medium size companies from the developing economies are ambitiously conducting clinical studies to win the approvals and expand the use of devices for new indications," said ABMRG's lead pipeline analyst Tammy Thomas.
The stent market globally and in the developed nations is controlled by three players - Abbott Laboratories, Boston Scientific, and Medtronic. While in developing economies, small and medium players from Asia and Europe have a considerable share in terms of volume.
The new market report "3 Catalysts to Catapult Global Coronary Stent Market to $13 Billion" discusses the key influencing factors across the geographies and draws estimates and forecasts based on in-depth analysis of market dynamics, assessment of coronary stent pipeline, unmet needs, regulatory and reimbursement environment.
The new global strategic business report on global coronary stents provides market size estimates and forecasts for 23 countries and major stent types Bare Metal Stent (BMS), DES and Bioresorbable Vascular Scaffolds (BVS) in terms of value and units, average selling prices, strategic insights about historical and future global markets (2005-2019). It also provides historical and forecasted numbers for PCI procedures. It highlights issues, market trends, growth drivers and restraints and the competitive landscape.
It reviews product approval status in major geographies, regulatory and reimbursement environment, industry consolidation (M&A) and partnerships. It compares estimated and forecasted market sizes of 23 leading countries, continents and economic regions. Around 70 companies from different levels of value chain are profiled with their product baskets and assets under the pipeline.
The report is useful for strategic planning, market entry strategy, sales forecast, product planning, product management, venture capitalists, investment banks, M&A, in-licensing and out-licensing, inventory and production planning and investor relations.
This detailed report is prepared by team of experienced sector analysts who used rigorous primary and secondary research, bottom-up approach, advanced computational, robust statistical and analytical models to forecast in detail all major stent types.
Browse full report with TOC at - http://www.abmrg.com/3-Catalysts-to-Catapult-Global-Coronary-Stent-Market-to-13-Billion.html
ABMRG (Ace Business and Market Research Group) is a high-end, full-service research firm focused on medical technology and pharmaceuticals. It offers comprehensive research and analytical studies targeting company, country, and sector, highlighting market dynamics, vital trends and business strategies. Its cutting edge reports empower companies to make smarter, effective and faster strategic decisions for business growth.